Recent progress on bile acid receptor modulators for treatment of metabolic diseases

Journal of Medicinal Chemistry

Volumn 59, Issue 14, 2016, Pages 6553-6579

  Xu, Yanping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; AGENTS AFFECTING METABOLISM; ANTHRANILIC ACID DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BILE ACID; BILE ACID DERIVATIVE; BILE ACID RECEPTOR; BILE ACID RECEPTOR MODULATOR; CHOLESTEROL; ERYTHRINA ALKALOID; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR AGONIST; FARNESOID X RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NATURAL PRODUCT; OBETICHOLIC ACID; SB 756050; TAUROCHOLIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIGAND;

AREA UNDER THE CURVE; CHOLESTASIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENERGY EXPENDITURE; GLUCOSE HOMEOSTASIS; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; IC50; INSULIN RESISTANCE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLIC DISEASES; METABOLISM;

BILE ACIDS AND SALTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; METABOLIC DISEASES; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84975700732     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00342     Document Type: Review

References (148)

1. Kuipers, F.; Bloks, V. W.; Groen, A. K. Beyond intestinal soap-bile acids in metabolic control Nat. Rev. Endocrinol. 2014, 10, 488-498 10.1038/nrendo.2014.60
2. Schaap, F. G.; Trauner, M.; Jansen, P. L. M. Bile acid receptors as targets for drug development Nat. Rev. Gastroenterol. Hepatol. 2014, 11, 55-67 10.1038/nrgastro.2013.151
3. Thomas, C.; Pellicciari, R.; Pruzanski, M.; Auwerx, J.; Schoonjans, K. Targeting bile-acid signalling for metabolic diseases Nat. Rev. Drug Discovery 2008, 7, 678-693 10.1038/nrd2619
4. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol. Cell 1999, 3, 543-553 10.1016/S1097-2765(00)80348-2
5. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lusting, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids Science 1999, 284, 1362-1365 10.1126/science.284.5418.1362
6. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Wilson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor Science 1999, 284, 1365-1368 10.1126/science.284.5418.1365
7. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, L. Identification of membrane-type receptor for bile acids (M-BAR) Biochem. Biophys. Res. Commun. 2002, 298, 714-719 10.1016/S0006-291X(02)02550-0
8. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids J. Biol. Chem. 2003, 278, 9435-9440 10.1074/jbc.M209706200
9. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 2009, 89, 147-191 10.1152/physrev.00010.2008
10. Lundquist, J. T., IV; Harnish, D. C.; Kim, C. Y.; Mehlmann, J. F.; Unwalla, R. J.; Phipps, K. M.; Crawley, M. L.; Commons, T.; Green, D. M.; Xu, W.; Hum, W.-T.; Eta, J. E.; Feingold, I.; Patel, V.; Evans, M. J.; Lai, K.; Borges-Marcucci, L.; Mahaney, P.; Wrobel, J. E. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates J. Med. Chem. 2010, 53, 1774-1787 10.1021/jm901650u
11. Richter, H. G.; Benson, G. M.; Blum, D.; Chaput, E.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R. E.; Plancher, J.-M.; Rudolph, M. G.; Schuler, F.; Taylor, S.; Bleicher, K. H. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes Bioorg. Med. Chem. Lett. 2011, 21, 191-194 10.1016/j.bmcl.2010.11.039
12. Cariou, B.; van Harmelen, K.; Duran-Sandoval, D.; van Dijk, T. H.; Grefhorst, A.; Abdelkarim, M.; Caron, S.; Torpier, G.; Fruchart, J.-C.; Gonzalez, F. J.; Kuipers, F.; Staels, B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J. Biol. Chem. 2006, 281, 11039-11049 10.1074/jbc.M510258200
13. Ma, K.; Saha, P. K.; Chan, L.; Moore, D. D. Farnesoid X receptor is essential for normal glucose homeostasis J. Clin. Invest. 2006, 116, 1102-1109 10.1172/JCI25604
14. Rizzo, G.; Disante, M.; Mencarelli, A.; Renga, B.; Gioiello, A.; Pellicciari, R.; Fiorucci, S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo Mol. Pharmacol. 2006, 70, 1164-1173 10.1124/mol.106.023820
15. Wang, X.; Jiang, T.; Levi, M. Nuclear hormone receptors in diabetic nephropathy Nat. Rev. Nephrol. 2010, 6, 342-351 10.1038/nrneph.2010.56
16. Keitel, V.; Cupisti, K.; Ullmer, C.; Knoefel, W. T.; Kubitz, R.; Haussinger, D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders Hepatology 2009, 50, 861-870 10.1002/hep.23032
17. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1 Biochem. Biophys. Res. Commun. 2005, 329, 386-390 10.1016/j.bbrc.2005.01.139
18. Sato, H.; Genet, C.; Strehle, A.; Thomas, C.; Lobstein, A.; Wagner, A.; Mioskowski, C.; Auwerx, J.; Saladin, R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea Biochem. Biophys. Res. Commun. 2007, 362, 793-798 10.1016/j.bbrc.2007.06.130
19. Watanabe, M.; Houten, S. M.; Mataki, C.; Christoffolete, M. A.; Kim, B. M.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 2006, 439, 484-489 10.1038/nature04330
20. Katsuma, S.; Hirasawa, A.; Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1 Biochem. Biophys. Res. Commun. 2005, 329, 386-390 10.1016/j.bbrc.2005.01.139
21. Sato, H.; Genet, C.; Strehle, A.; Thomas, C.; Lobstein, A.; Wagner, A.; Mioskowski, C.; Auwerx, J.; Saladin, R. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea Biochem. Biophys. Res. Commun. 2007, 362, 793-798 10.1016/j.bbrc.2007.06.130
22. Adrian, T. E.; Gariballa, S.; Parekh, K. A.; Thomas, S. A.; Saadi, H.; Al Kaabi, J.; Nagelkerke, N.; Gedulin, B.; Young, A. A. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers Diabetologia 2012, 55, 2343-2347 10.1007/s00125-012-2593-2
23. Keitel, V.; Reinehr, R.; Gatsios, P.; Rupprecht, C.; Görg, B.; Selbach, O.; Häussinger, D.; Kubitz, R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells Hepatology 2007, 45, 695-704 10.1002/hep.21458
24. Haselow, K.; Bode, J. G.; Wammers, M.; Ehlting, C.; Keitel, V.; Kleinebrecht, L.; Schupp, A.-K.; Häussinger, D.; Graf, D. Bile acids PKA-dependently induce a switch of the IL-10/IL-12 ratio and reduce proinflammatory capability of human macrophages J. Leukocyte Biol. 2013, 94 (6) 1253-1264 10.1189/jlb.0812396
25. Yoneno, K.; Hisamatsu, T.; Shimamura, K.; Kamada, N.; Ichikawa, R.; Kitazume, M. T.; Mori, M.; Uo, M.; Namikawa, Y.; Matsuoka, K.; Sato, T.; Koganei, K.; Sugita, A.; Kanai, T.; Hibi, T. TGR5 signaling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease Immunology 2013, 139 (1) 19-29 10.1111/imm.12045
26. Keitel, V.; Spomer, L.; Marin, J. J. G.; Williamson, C.; Geenes, V.; Kubitz, R.; Häussinger, D.; Macias, R. I. R. Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term Placenta 2013, 34 (9) 810-816 10.1016/j.placenta.2013.06.302
27. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Palladino, G.; Cipriani, S. Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment Curr. Med. Chem. 2010, 17, 139-159 10.2174/092986710790112666
28. Sharma, R.; Long, A.; Gilmer, J. F. Advances in bile acid medicinal chemistry Curr. Med. Chem. 2011, 18, 4029-4052 10.2174/092986711796957266
29. Fiorucci, S.; Mencarelli, A.; Distrutti, E.; Zampella, A. Farnesoid X receptor: from medicinal chemistry to clinical applications Future Med. Chem. 2012, 4, 877-891 10.4155/fmc.12.41
30. Merk, D.; Steinhilber, D.; Schubert-Zsilavecz, M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators Future Med. Chem. 2012, 4, 1015-1036 10.4155/fmc.12.47
31. Xu, Y. Bile acid receptor modulators in metabolic diseases Annu. Rep. Med. Chem. 2011, 46, 69-87 10.1016/B978-0-12-386009-5.00022-9
32. Gioiello, A.; Rosatelli, E.; Nuti, R.; Macchiarulo, A.; Pellicciari, R. Patented TGR5 modulators: a review (2006-present) Expert Opin. Ther. Pat. 2012, 22, 1399-1414 10.1517/13543776.2012.733000
33. Macchiarulo, A.; Gioiello, A.; Pellicciari, R. TGR5 agonists in development. In New Therapeutic Strategies for Type 2 Diabetes; RSC Drug Discovery Series; Royal Society of Chemistry: Cambridge, UK, 2012; Vol. 27, chapter 10, pp 270-305, DOI 10.1039/9781849735322-00270
34. Zhang, Y.; Lee, F. Y.; Barrera, G.; Lee, H.; Vales, C.; Gonzalez, F. J.; Willson, T. M.; Edwards, P. A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1006-1011 10.1073/pnas.0506982103
35. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H.-U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 2013, 145, 574-582 10.1053/j.gastro.2013.05.042
36. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. Identification of a chemical tool for the orphan nuclear receptor FXR J. Med. Chem. 2000, 43, 2971-2974 10.1021/jm0002127
37. Bass, J. Y.; Caldwell, R. D.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Parks, D. J.; Todd, D.; Williams, S. P.; Wisely, G. B. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064 Bioorg. Med. Chem. Lett. 2009, 19, 2969-2973 10.1016/j.bmcl.2009.04.047
38. Akwabi-Ameyaw, A.; Bass, J. Y.; Caldwell, R. D.; Caravella, J. A.; Chen, L.; Creech, K. L.; Deaton, D. N.; Jones, S. A.; Kaldor, I.; Liu, Y.; Madauss, K. P.; Marr, H. B.; McFadyen, R. B.; Miller, A. B.; Navas, F., III; Parks, D. J.; Spearing, P. K.; Todd, D.; Williams, S. P.; Wisely, G. B. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064 Bioorg. Med. Chem. Lett. 2008, 18, 4339-4343 10.1016/j.bmcl.2008.06.073
39. Feng, S.; Yang, M.; Zhang, Z.; Wang, Z.; Hong, D.; Richter, H.; Benson, G. M.; Bleicher, K.; Grether, U.; Martin, R. E.; Plancher, J.-M.; Kuhn, B.; Rudolph, M. G.; Chen, L. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist Bioorg. Med. Chem. Lett. 2009, 19, 2595-2598 10.1016/j.bmcl.2009.03.008
40. Flatt, B.; Martin, R.; Wang, T.-L.; Mahaney, P.; Murphy, B.; Gu, X.-H.; Foster, P.; Li, J.; Pircher, P.; Petrowski, M.; Schulman, I.; Westin, S.; Wrobel, J.; Yan, G.; Bischoff, E.; Daige, C.; Mohan, R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR) J. Med. Chem. 2009, 52, 904-907 10.1021/jm8014124
41. Benson, G. M.; Bleicher, K.; Grether, U.; Martin, R. E.; Plancher, J.-M.; Richter, H.; Taylor, S.; Yang, M. Benzimidazole derivatives used as FXR agonists. WO2009/027264-A1, 2009.
42. Richter, H. G. F.; Benson, G. M.; Bleicher, K. H.; Blum, D.; Chaput, E.; Clemann, N.; Feng, S.; Gardes, C.; Grether, U.; Hartman, P.; Kuhn, B.; Martin, R. E.; Plancher, J.-M.; Rudolph, M. G.; Schuler, F.; Taylor, S. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties Bioorg. Med. Chem. Lett. 2011, 21, 1134-1140 10.1016/j.bmcl.2010.12.123
43. Benson, G. M.; Bleicher, K.; Grether, U.; Martin, R. E.; Plancher, J.-M.; Richter, H.; Taylor, S.; Yang, M. Novel methyl-benzimidazole derivatives. WO2009/062874-A2, 2009.
44. Benson, G. M.; Bleicher, K.; Chucholowski, A.; Dehmlow, H.; Grether, U.; Kuhn, B.; Martin, R. E.; Niesor, E. J.; Panday, N.; Richter, H.; Schuler, F.; Warot, X. M.; Wright, M.; Yang, M. Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same. WO000643 A1, 2008.
45. Marinozzi, M.; Carotti, A.; Sardella, R.; Buonerba, F.; Ianni, F.; Natalini, B.; Passeri, D.; Rizzo, G.; Pellicciari, R. Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity Bioorg. Med. Chem. 2013, 21, 3780-3789 10.1016/j.bmc.2013.04.038
46. Merk, D.; Gabler, M.; Gomez, R. C.; Flesch, D.; Hanke, T.; Kaiser, A.; Lamers, C.; Werz, O.; Schneider, G.; Schubert-Zsilavecz, M. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR) Bioorg. Med. Chem. 2014, 22, 2447-2460 10.1016/j.bmc.2014.02.053
47. Merk, D.; Lamers, C.; Ahmad, K.; Gomez, R. C.; Schneider, G.; Steinhilber, D.; Schubert-Zsilavecz, M. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist J. Med. Chem. 2014, 57, 8035-8055 10.1021/jm500937v
48. Flesch, D.; Gabler, M.; Lill, A.; Gomez, R. C.; Steri, R.; Schneider, G.; Stark, H.; Schubert-Zsilavecz, M.; Merk, D. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties Bioorg. Med. Chem. 2015, 23, 3490-3498 10.1016/j.bmc.2015.04.035
49. Mehlmann, J. F.; Lundquist, J. T.; Mahaney, P. E.; Crawley, M. L.; Kim, C. Y. 1,4,5,6,7,8-Hexahydro-pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepine as modulators of nuclear receptor activity. U.S. Patent 0,131,409, 2009.
50. Mehlmann, J. F.; Lundquist, J. T.; Mahaney, P. E.; Crawley, M. L.; Kim, C. Y. 1,4,5,6-Tetrahydro-pyrrolo[2,3-d]azepines and -imidazo[4,5-d]azepines as modulators of nuclear receptor activity. U.S. Patent 0,137,554, 2009.
51. Roche, D.; Mautino, G.; Kober, I.; Contard, F.; Christmann-Franck, S.; Sengupta, S.; Sistla, R.; Rao, G. V. Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators. WO2009/127321-A1, 2009.
52. Roche, D.; Mautino, G.; Kober, I.; Contard, F.; Christmann-Franck, S.; Kober, I.; Sengupta, S.; Sistla, R.; Rao, G. V. Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators. EP2009/2110374, 2009.
53. Akwabi-Ameyaw, A.; Deaton, D. N.; McFadyen, R. B.; Navas, F., III. Farnesoid X receptor agonists. WO2009/005998-A1, 2009.
54. Benson, G. M.; Bleicher, K.; Feng, S.; Grether, U.; Kuhn, B.; Martin, R. E.; Plancher, J.-M.; Richter, H.; Taylor, S. New benzimidazole derivatives. WO2010/043513-A1, 2010.
55. Benson, G. M.; Bleicher, K.; Feng, S.; Grether, U.; Kuhn, B.; Martin, R. E.; Plancher, J.-M.; Richter, H.; Taylor, S. Benzimidazole derivatives. 0,093,818, 2010.
56. Abel, U.; Kremoser, C. Heterocyclic cyclopropyl-substituted FXR binding compounds. WO2009/149795-A2, 2009.
57. Kremoser, C.; Abel, U.; Steeneck, C.; Kinzel, O. Novel FXR (NR1H4) binding and activity modulating compounds. WO2011/020615-A1, 2011.
58. Kremoser, C.; Boes, M. Novel FXR (NR1H4) binding and activity modulating compounds. EP2289883 A1, 2011.
59. Kinzel, O.; Steeneck, C.; Kremoser, C. Novel FXR (NR1H4) binding and activity modulating compounds. EP2545964 A1, 2013.
60. Kinzel, O.; Steeneck, C.; Kremoser, C. Novel FXR (NR1H4) binding and activity modulating compounds. WO2013/007387-A1, 2013.
61. Tully, D. C.; Vidal, A.; Mutnick, D.; Alper, P. B. Compositions and methods for modulating farnesoid X receptors. WO2012/087520-A1, 2012.
62. Tully, D. C.; Chanelli, D. Compositions and methods for modulating farnesoid X receptors. WO2012/087521-A1, 2012.
63. Tully, D. C.; Rucker, P. V.; Alper, P. B.; Mutnick, D.; Chanelli, D. Compositions and methods for modulating FXR. WO2012/087519-A1, 2012.
64. Benson, G. M.; Bleicher, K.; Feng, S.; Grether, U.; Kuhn, B.; Martin, R. E.; Plancher, J.-M.; Richter, H.; Rudolph, M.; Taylor, S. New benzimidazole derivatives. US2011/0077273, 2011.
65. Benson, G. M.; Bleicher, K.; Grether, U.; Kuhn, B.; Richter, H.; Taylor, S. Cyclopentyl- and cycloheptylpyrazole as FXR modulators. WO2011/117163, 2011.
66. Hambruch, E.; Miyazaki-Anzai, S.; Hahn, U.; Matysik, S.; Boettcher, A.; Perovic-Ottstadt, S.; Schluter, T.; Kinzel, O.; Krol, H. D.; Deuschle, U.; Burnet, M.; Levi, M.; Schmitz, G.; Miyazaki, M.; Kremoser, C. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor(-/-) mice J. Pharmacol. Exp. Ther. 2012, 343, 556-567 10.1124/jpet.112.196519
67. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H.-U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 2013, 145 (3) 574-582 10.1053/j.gastro.2013.05.042
68. Urizar, N. L.; Liverman, A. B.; Dodds, D. T.; Silva, F. V.; Ordentlich, P.; Yan, Y.; Gonzalez, F. J.; Heyman, R. A.; Mangelsdorf, D. J.; Moore, D. D. A Natural product that lowers cholesterol as an antagonist ligand for FXR Science 2002, 296 (5573) 1703-1706 10.1126/science.1072891
69. Kainuma, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of non-steroidal farnesoid X recptor (FXR) antagonist Bioorg. Med. Chem. 2007, 15, 2587-2600 10.1016/j.bmc.2007.01.046
70. Huang, H.; Yu, Y.; Gao, Z.; Zhang, Y.; Li, C.; Xu, X.; Jin, H.; Yan, W.; Ma, R.; Zhu, J.; Shen, X.; Jiang, H.; Chen, L.; Li, J. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists J. Med. Chem. 2012, 55, 7037-7053 10.1021/jm3002718
71. Huang, H.; Si, P.; Wang, L.; Xu, Y.; Xu, X.; Zhu, J.; Jiang, H.; Li, W.; Chen, L.; Li, J. Design, synthesis, and biological evaluation of novel nonsteroidal farnesoid X receptor (FXR) antagonists: molecular basis of FXR antagonism ChemMedChem 2015, 10, 1184-1199 10.1002/cmdc.201500136
72. Liu, P.; Xu, X.; Chen, L.; Ma, L.; Shen, X.; Hu, L. Discovery and SAR study of hydroxyacetophenone derivatives as potent, non-steroidal farnesoid X receptor (FXR) antagonists Bioorg. Med. Chem. 2014, 22, 1596-1607 10.1016/j.bmc.2014.01.032
73. Yu, D. D.; Lin, W.; Forman, B. M.; Chen, T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor Bioorg. Med. Chem. 2014, 22, 2919-2938 10.1016/j.bmc.2014.04.014
74. Song, K.; Xu, X.; Liu, P.; Chen, L.; Shen, X.; Liu, J.; Hu, L. Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists Bioorg. Med. Chem. 2015, 23, 6427-6436 10.1016/j.bmc.2015.08.021
75. Xu, X.; Xu, X.; Liu, P.; Zhu, Z.; Chen, J.; Fu, H.; Chen, L.; Hu, L.; Shen, X. Structrual basis for small molecule NDB (N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2,6-dichloro-4-(dimethylamino)benzamide) as a selective antagonist of farnesoid X receptor α (FXRα) in stabilizing the homodimerization of the receptor J. Biol. Chem. 2015, 290, 19888-19899 10.1074/jbc.M114.630475
76. Zhou, G.; Huang, Z.; Liu, Z.; Sheng, D.; Nie, X.; Wang, D. 14-Aryl ether andrographolide derivative useful in treatment of FXR-related diseases and its preparation. (Faming Zhuanli Shenqing) CN103224492 A, 2013.
77. Sepe, V.; Bifulco, G.; Renga, B.; D'Amore, C.; Fiorucci, S.; Zampella, A. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor J. Med. Chem. 2011, 54, 1314-1320 10.1021/jm101336m
78. Sepe, V.; Ummarino, R.; D'Auria, M. V.; Taglialatela-Scafati, O.; De Marino, S.; D'Amore, C.; Renga, B.; Chini, M. G.; Bifulco, G.; Nakao, Y.; Fusetani, N.; Fiorucci, S.; Zampella, A. Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge theonella swinhoei Mar. Drugs 2012, 10, 2448-2466 10.3390/md10112448
79. Renga, B.; Mencarelli, A.; D'Amore, C.; Cipriani, S.; D'Auria, A. V.; Sepe, V.; Chini, M. G.; Monti, M. C.; Bifulco, G.; Zampella, A.; Fiorucci, S. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis PLoS One 2012, 7, e30443 10.1371/journal.pone.0030443
80. Di Leva, F. S.; Festa, C.; D'Amore, C.; De Marino, S.; Renga, B.; D'Auria, M. V.; Novellino, E.; Limongelli, V.; Zampella, A.; Fiorucci, S. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands J. Med. Chem. 2013, 56, 4701-4717 10.1021/jm400419e
81. Evans, K. A.; Budzik, B. W.; Ross, S. A.; Wisnoski, D. D.; Jin, J.; Rivero, R. A.; Vimal, M.; Szewczyk, G. R.; Jayawickreme, C.; Moncol, D. L.; Rimele, T. J.; Armour, S. L.; Weaver, S. P.; Griffin, R. J.; Tadepalli, S. M.; Jeune, M. R.; Shearer, T. W.; Chen, Z. B.; Chen, L.; Anderson, D. L.; Becherer, J. D.; De Los Frailes, M.; Colilla, F. J. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists J. Med. Chem. 2009, 52, 7962-7965 10.1021/jm901434t
82. Budzik, B. W.; Evans, K. A.; Wisnoski, D. D.; Jin, J.; Rivero, R. A.; Szewczyk, G. R.; Jayawickreme, C.; Moncol, D. L.; Yu, H. Synthesis and structure-activity relationships of a series of 3-aryl-4-isoxazolecarboxamides as a new class of TGR5 agonists Bioorg. Med. Chem. Lett. 2010, 20, 1363-1367 10.1016/j.bmcl.2010.01.003
83. Herbert, M. R.; Siegel, D. L.; Staszewski, L.; Cayanan, C.; Banerjee, U.; Dhamija, S.; Anderson, J.; Fan, A.; Wang, L.; Rix, P.; Shiau, A. K.; Rao, T. S.; Noble, S. A.; Heyman, R. A.; Bischoff, E.; Guha, M.; Kabakibi, A.; Pinkerton, A. B. Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5 Bioorg. Med. Chem. Lett. 2010, 20, 5718-5721 10.1016/j.bmcl.2010.08.014
84. Pinkerton, A. B.; Kabakibi, A.; Herbert, M. R.; Seigel, D. L. Heterocyclic modulators of TGR5 for treatment of disease. WO2008/097976-A1, 2008.
85. Martin, R. E.; Bissantz, C.; Gavelle, O.; Kuratli, C.; Dehmlow, H.; Richter, H. G. F.; Obst Sander, U.; Erickson, S. D.; Kim, K.; Pietranico-Cole, S. L.; Alvarez-Sanchez, R.; Ullmer, C. 2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5) ChemMedChem 2013, 8, 569-576 10.1002/cmdc.201200474
86. Park, E. J.; Ahn, Y. G.; Jung, S. H.; Bang, H. J.; Kim, M.; Hong, D. J.; Kim, J.; Suh, K. H.; Kim, Y. J.; Kim, D.; Kim, E.-Y.; Lee, K.; Min, K. H. Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonist Bioorg. Med. Chem. Lett. 2014, 24, 4271-4275 10.1016/j.bmcl.2014.07.026
87. Itoh, F.; Tawaraishi, T.; Hirohashi, M. Fused ring compound. JP2006/056881-A, 2006.
88. Zhu, J.; Ning, M.; Guo, C.; Zhang, L.; Pan, G.; Leng, Y.; Shen, J. Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on 4-phenyl pyridine scaffold Eur. J. Med. Chem. 2013, 69, 55-68 10.1016/j.ejmech.2013.07.050
89. Zhu, J.; Ye, Y.; Ning, M.; Mandi, A.; Feng, Y.; Zou, Q.; Kurtan, T.; Leng, Y.; Shen, J. Design, synthesis and structure-activity relationship of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists ChemMedChem 2013, 8, 1210-1223 10.1002/cmdc.201300144
90. Phillips, D. P.; Gao, W.; Yang, Y.; Zhang, G.; Lerario, I. K.; Lau, T. L.; Jiang, J.; Wang, X.; Nguyen, D. G.; Bhat, B. G.; Trotter, C.; Sullivan, H.; Welzel, G.; Landry, J.; Chen, Y.; Joseph, S. B.; Li, C.; Gordon, W. P.; Richmond, W.; Johnson, K.; Bretz, A.; Bursulaya, B.; Pan, S.; McNamara, P.; Seidel, H. M. Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy J. Med. Chem. 2014, 57, 3263-3282 10.1021/jm401731q
91. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolipyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 2003, 46, 2774-2789 10.1021/jm030091l
92. Dehmlow, H.; Alvarez Sanchez, R. A.; Bachmann, S.; Bissantz, C.; Bliss, F.; Conde-Knape, K.; Graf, M.; Martin, R. E.; Obst Sander, U.; Raab, S.; Richter, H. G. F.; Sewing, S.; Sprecher, U.; Ullmer, C.; Mattei, P. Discovery and optimization of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists Bioorg. Med. Chem. Lett. 2013, 23, 4627-4632 10.1016/j.bmcl.2013.06.017
93. Londregan, A. T.; Piotrowski, D. W.; Futatsugi, K.; Warmus, J. S.; Boehm, M.; Carpino, P. A.; Chin, J. E.; Janssen, A. M.; Roush, N. S.; Buxton, J.; Hinchey, T. Discovery of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides as potent agonists of TGR5 via sequential combinatorial libraries Bioorg. Med. Chem. Lett. 2013, 23, 1407-1411 10.1016/j.bmcl.2012.12.076
94. Szewczyk, J. R.; Laudeman, C. P.; Evans, K. A.; Li, Y. H.; Dock, S. T.; Chen, Z. Chemical compounds. WO2007/127505-A2, 2007.
95. Herbert, M. R.; Pinkerton, A. B.; Seigel, D. L. Heterocyclic modulators of TGR5 for treatment of disease. WO2010/016846-A1, 2010.
96. Herbert, M. R.; Pinkerton, A. B.; Seigel, D. L. Heterocyclic modulators of TGR5 for treatment of disease. U.S. Patent 0,054,304, 2009.
97. Smith, N. D.; Payne, J. E.; Hoffman, T. Z. Heterocyclic modulators of TGR5 for treatment of disease. WO2010/014739-A2, 2010.
98. Smith, N. D.; Payne, J. E.; Hoffman, T. Z.; Bonnefous, C.; Pinkerton, A. B.; Seigel, D. L. Heterocyclic modulators of TGR5. WO2009/026241-A1, 2009.
99. Pinkerton, A. B.; Kabakibi, A.; Hoffman, T. Z.; Seigel, D. L.; Noble, S. A. Quinazolinone modulator of TGR5. WO2008/067219-A2, 2008.
100. Pinkerton, A. B.; Kabakibi, A.; Gahman, T. C. Heterocyclic modulators of TGR5. WO2008/067222-A1, 2008.
101. Itoh, F.; Hinuma, S.; Kanzaki, N.; Miki, T.; Kawamata, Y.; Oi, S.; Tawaraishi, T.; Ishichi, Y.; Hirohashi, M. Receptor agonists. WO2004/067008-A1, 2004.
102. Itoh, F.; Hinuma, S.; Kanzaki, N.; Miki, T.; Kawamata, Y.; Oi, S.; Tawaraishi, T.; Ishichi, Y.; Hirohashi, M. Receptor agonist. U.S. Patent 0,199,795, 2006.
103. Itoh, F.; Nicolas, H. Receptor agonist. JP2006/063064-A, 2006.
104. Bissantz, C.; Dehmlow, H.; Martin, R. E.; Sander, U. O.; Richter, H.; Ullmer, C. Novel phenyl amide or pyridyl amide derivatives. U.S. Patent 0,105,906, 2010.
105. Arista, L.; Hogenauer, K.; Schmiedeberg, N.; Werner, G.; Jaksche, H. Amide derivatives and their application for the treatment of G protein related diseases. WO2007/110237-A2, 2007.
106. Arista, L. Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists. WO2008/125627-A1, 2008.
107. Bollu, V.; Boren, B. C.; Dalgard, J. E.; Flatt, B. T.; Hudson, S.; Mohan, R.; Morrissey, M.; Pratt, B.; Wang, T.-L. Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity. WO2010/093845-A1, 2010.
108. Sugimoto, Y.; Satoh, A.; Nishimura, T. Novel isoquinoline derivatives. WO2010/117084-A1, 2010.
109. Arakawa, K.; Sugimoto, Y.; Sasaki, Y.; Satoh, A.; Nishimura, T. Novel isoquinolinyloxy-methyl heteroaryl derivatives. WO2010/117090-A1, 2010.
110. Robl, J.; Li, J.; Kennedy, L. J.; Walker, S. J.; Wang, H.; Burn, W. N.; Ahmad, S.; Ngu, K. Novel bicyclic nitrogen containing heteroaryl TGR5 receptor modulators. WO2012/149236-A1, 2012.
111. Bissantz, C.; Dehmlow, H.; Erickson, S. D.; Karnachi, P.; Kim, K.; Martin, R. E.; Mattei, P.; Obst Sander, U.; Pietranica-cole, S. L.; Richter, H.; Ullmer, C. 3-Amino-pyridines as GPBAR1 agonists. WO2012/117000-A1, 2012.
112. Bissantz, C.; Dehmlow, H.; Erickson, S. D.; Kim, K.; Martin, R. E.; Mattei, P.; Obst Sander, U.; Pietranica-cole, S. L.; Richter, H.; Ullmer, H. 1-Hydroxyimino-3-phenyl-propanes. US2012/0010190-A1, 2012.
113. Gao, W.; Lau, T.; Pan, S.; Phillips, D. P.; Wang, X.; Yang, Y. Compounds and compositions as TGR5 agonists. WO2012/082947-A1, 2012.
114. Agarwal, S.; Desal, R. C. Heterocyclic compounds and their use for treatment of diabetes, obesity or related disorders. WO2013/164838-A1, 2013.
115. Agarwal, S.; Jain, M. R.; Patel, P. R. 2-Thio-imidazole derivatives as TGR5 modulators. WO2013/054338-A1, 2013.
116. Agarwal, S.; Desal, R. C. Novel compounds for treatment of diabetes, obesity or related disorders. WO2013/102929-A1, 2013.
117. Goff, D.; Payan, D. G.; Braselmann, S. Synthesis of polycyclic alkaloids and their use as TGR5 agonists. WO2013/134527-A1, 2013.
118. Dutt, C.; Chauthaiwale, V.; Gupta, R. C.; Ghalsasi, S.; Tuli, D.; Deshpande, S.; Chaudhari, A.; Zambad, S. Novel substituted imidazopyrimidines as GPBAR1 receptor modulators. WO2013/057650-A1, 2013.
119. Dehmilow, H.; Martin, R. E.; Mattei, P.; Obst Sander, U.; Richter, H. 1-Cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes. WO2013/060653-A1, 2013.
120. Dehmilow, H.; Martin, R. E.; Mattei, P.; Obst Sander, U.; Richter, H. 1-Pyridazinyl-hydroxyimino-3-phenyl-propanes. US2013/0123267-A1, 2013.
121. Dehmilow, H.; Erickson, S. D.; Mattei, P.; Richter, H. 1,2-Pyridazine, 1,6-pyridazine or pyrimidine, -benzamide derivatives as GPBAR1 modulators. WO2013/149977-A1, 2013.
122. Smith, E. D.; Fitzgerald, M. E.; Jiang, R.; Atkinson, R. N.; Veal, J. M.; Huang, K. H. Arylsubstituted thiazolotriazoles and thiazoloimidazoles. WO2013/049585-A1, 2013.
123. Leng, Y.; Shen, J.; Duan, H.; Ning, M. Preparation of heterocycles useful for treating TGR5-mediated diseases. (Faming Zhuanli Shenqing) CN102850321 A20130102, 2013.
124. Shen, J.; Leng, Y.; Zhu, J.; Ning, M. Preparation of five-membered azole-type heterocyclic compounds for preventing or treating TGR5-mediated diseases. (Faming Zhuanli Shenqing) CN103864754 A20140618, 2014.
125. Piotrowski, D. W.; Futatsugi, K.; Warmus, J. S.; Orr, S. T. M.; Freeman-Cook, K. D.; Londregan, A. T.; Wei, L.; Jennings, S. M.; Herr, M.; Coffey, S. B.; Jiao, W.; Storer, G.; Hepworth, D.; Wang, J.; Lavergne, S. Y.; Chin, J. E.; Hadcock, J. R.; Brenner, M. B.; Wolford, A. C.; Janssen, A. M.; Roush, N. S.; Buxton, J.; Hinchey, T.; Kalgutkar, A. S.; Sharma, R.; Flynn, D. A. Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists ACS Med. Chem. Lett. 2013, 4, 63-68 10.1021/ml300277t
126. Futatsugi, K.; Bahnck, K. B.; Brenner, M. B.; Buxton, J.; Chin, J. E.; Coffey, S. B.; Dubins, J.; Flynn, D.; Gautreau, D.; Guzman-Perez, A.; Hadcock, J. R.; Hepworth, D.; Herr, M.; Hinchey, T.; Janssen, A. M.; Jennings, S. M.; Jiao, W.; Lavergne, S. Y.; Li, B.; Li, M.; Munchhof, M. J.; Orr, S. T. M.; Piotrowski, D. W.; Roush, N. S.; Sammons, M.; Stevens, B. D.; Storer, G.; Wang, J.; Warmus, J. S.; Wei, L.; Wolford, A. C. Optimization of triazole-based TGR5 agonists towards orally available agents MedChemComm 2013, 4, 205-210 10.1039/C2MD20174G
127. Duan, H.; Ning, M.; Chen, X.; Zou, Q.; Zhang, L.; Feng, Y.; Zhang, L.; Leng, Y.; Shen, J. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists J. Med. Chem. 2012, 55, 10475-10489 10.1021/jm301071h
128. Zou, Q.; Duan, H.; Ning, M.; Liu, N. J.; Feng, Y.; Zhang, L.; Zhu, J.; Leng, Y.; Shen, J. 4-Benzofuranyloxynicotinamide derivatives are potent and orally available TGR5 Agonists Eur. J. Med. Chem. 2014, 82, 1-15 10.1016/j.ejmech.2014.05.031
129. Duan, H.; Ning, M.; Zou, Q.; Ye, Y.; Feng, Y.; Zhang, L.; Leng, Y.; Shen, J. Discovery of intestinal targeted TGR5 agonsits for the treatment of type 2 diabetes J. Med. Chem. 2015, 58, 3315-3328 10.1021/jm500829b
130. Lewis, J. G.; Reich, N.; Chen, T.; Jacobs, J. W.; Charmot, D.; Navre, M.; Finn, P.; Carreras, C.; Spencer, A. Nonsystemic TGR5 agonist. WO2013/096771-A1, 2013.
131. Flatt, B. T.; Mohan, R. TGR5 agonists: imidazole and triazole compounds containing a quaternary nitrogen. WO2014/100021-A1, 2014.
132. Flatt, B. T.; Mohan, R. TGR5 agonists having an imidazole or triazole core with substituent having a quaternary nitrogen. WO2014/100025-A1, 2014.
133. Pellicciari, R.; Gioiello, A.; Macchiarulo, A.; Thomas, C.; Rosatelli, E.; Natalini, E.; Sardella, R.; Pruzanski, M.; Roda, A.; Pastorini, E.; Schoonjans, K.; Auwerx, J. Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity J. Med. Chem. 2009, 52, 7958-7961 10.1021/jm901390p
134. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab. 2009, 10, 167-177 10.1016/j.cmet.2009.08.001
135. Pellicciari, R.; Gioiello, A.; Sabbatini, P.; Venturoni, F.; Nuti, R.; Colliva, C.; Rizzo, G.; Adorini, L.; Pruzanski, M.; Roda, A.; Macchiarulo, A. Avicholic acid: a lead compound form birds on the route to potent TGR5 modulators ACS Med. Chem. Lett. 2012, 3, 273-277 10.1021/ml200256d
136. Yu, D.; Forman, B.; Huang, W.; Sousa, K. Bile acid analog TGR5 agonists. US2014/0206657-A1, 2014.
137. Rizzo, G.; Passeri, D.; De Franco, F.; Ciaccioli, G.; Donadio, L.; Rizzo, G.; Orlandi, S.; Sadeghpour, B.; Wang, X. X.; Jiang, T.; Levi, M.; Pruzanski, M.; Adorini, L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist Mol. Pharmacol. 2010, 78, 617-630 10.1124/mol.110.064501
138. D'Amore, D.; Di Leva, F. S.; Sepe, V.; Renga, B.; Del Gaudio, C.; D'Auria, M. V.; Zampella, A.; Fiorucci, S.; Limongelli, V. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and memberane bile acid receptors J. Med. Chem. 2014, 57, 937-954 10.1021/jm401873d
139. Pellicciari, R.; Fiorucci, S.; Camaioni, E.; Clerici, C.; Costantino, G.; Maloney, P. R.; Morelli, A.; Parks, D. J.; Willson, T. M. 6a-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity J. Med. Chem. 2002, 45, 3569-3572 10.1021/jm025529g
140. Mudaliar, S.; Henry, R. R.; Sanyal, A. J.; Morrow, L.; Marschall, H.-U.; Kipnes, M.; Adorini, L.; Sciacca, C. I.; Clopton, P.; Castelloe, E.; Dillon, P.; Pruzanski, M.; Shapiro, D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease Gastroenterology 2013, 145, 574-582 10.1053/j.gastro.2013.05.042
141. Neuschwander-Tetri, B. A.; Loomba, R.; Sanyal, A. J.; Lavine, J. E.; Van Natta, M. L.; Abdelmalek, M. F.; Chalasani, N.; Dasarathy, S.; Diehl, A. M.; Hameed, B.; Kowdley, K. V.; McCullough, A.; Terrault, N.; Clark, J. M.; Tonascia, J.; Brunt, E. M.; Kleiner, D. E.; Doo, E.; For the NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial Lancet 2015, 385 (9972) 956-965 10.1016/S0140-6736(14)61933-4
142. FXR agonist Px-102 improves hepatic steatosis in NAFLD mouse models. The Asian Pacific Association for the Study of the Liver: "APASL Liver Week", Singapore, June 6-10, 2013.
143. Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients; ClinicalTrials.gov; National Institutes of Health: Bethesda, MD, November 19, 2013; https://clinicaltrials.gov/ct2/show/NCT01999101?term=Px-104&rank=1.
144. According to Scrip's Pipeline Watch (as of April 2010): http://www.scripintelligence.com/multimedia/archive/00090/Scrip-3490-Pipeline-90699a.pdf.
145. Wu, T.; Bound, M. J.; Standfield, S. D.; Jones, K. L.; Horowitz, M.; Rayner, C. K. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans J. Clin. Endocrinol. Metab. 2013, 98 (4) E718-E722 10.1210/jc.2012-3961
146. According to Satiogen website (as of January 2016): http://satiogen.com/.
147. Fang, S.; Suh, J. M.; Reilly, S. M.; Yu, E.; Osborn, O.; Lackey, D.; Yoshihara, E.; Perino, A.; Jacinto, S.; Lukasheva, Y.; Atkins, A. R.; Khvat, A.; Schnabl, B.; Yu, R. T.; Brenner, D. A.; Coulter, S.; Liddle, C.; Schoonjans, K.; Olefsky, J. M.; Saltiel, A. R.; Downes, M.; Evans, R. M. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance Nat. Med. 2015, 21, 159-167 10.1038/nm.3760
148. Ryan, K. K.; Tremaroli, V.; Clemmensen, C.; Kovatcheva-Datchary, P.; Myronovych, A.; Karns, R.; Wilson-Pérez, H. E.; Sandoval, D. A.; Kohli, R.; Bäckhed, F.; Seeley, R. J. FXR is a molecular target for the effects of vertical sleeve gastrectomy Nature 2014, 509, 183-190 10.1038/nature13135